DRUGS & SUPPLEMENTS
How is the drug helping you?
Flurbiren (Flurbiprofen Sodium)® ophthalmic solution is indicated for the inhibition of intraoperative miosis.
Flurbiren (Flurbiprofen Sodium)® ophthalmic solution is contraindicated in individuals who are hypersensitive to any components of the medication.
With some nonsteroidal anti-inflammatory drugs, there exists the potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that Flurbiren (Flurbiprofen Sodium)® ophthalmic solution may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery.
There is the potential for cross-sensitivity to acetylsalicylic acid and other non-steroidal anti-inflammatory drugs. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.
Topical nonsteroidal anti-inflammatory drugs may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.
It is recommended that Flurbiren (Flurbiprofen Sodium)® ophthalmic solution be used with caution in surgical patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time.
Patients should be instructed to avoid allowing the tip of the bottle to contact the eye or surrounding structures because this could cause the tip to become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.
To avoid the potential for cross-contamination, the patient should be advised to use one bottle for each eye with bilateral ocular surgery. The use of the same bottle of eye drops for both eyes is not recommended with ocular surgery.
Interaction of Flurbiren ® ophthalmic solution with other topical ophthalmic medications has not been fully investigated.
Although clinical studies with acetylcholine chloride and animal studies with acetylcholine chloride or carbachol revealed no interference, and there is no known pharmacological basis for an interaction, there have been reports that acetylcholine chloride and carbachol have been ineffective when used in patients treated with Flurbiren (Flurbiprofen Sodium)® ophthalmic solution.
Long-term studies in mice and/or rats have shown no evidence of carcinogenicity with flurbiprofen. Long-term mutagenicity studies in animals have not been performed.
Pregnancy Category C
Flurbiprofen has been shown to be embryocidal, delay parturition, prolong gestation, reduce weight, and/or slightly retard growth of fetuses when given to rats in daily oral doses of 0.4 mg/kg and above.
There are no adequate and well-controlled studies in pregnant women. Flurbiren (Flurbiprofen Sodium)® ophthalmic solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Flurbiren (Flurbiprofen Sodium), a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Safety and effectiveness in pediatric patients have not been established.
No overall differences in safety or effectiveness have been observed between elderly and younger patients.
Transient burning and stinging upon instillation and other minor symptoms of ocular irritation have been reported with the use of Flurbiren (Flurbiprofen Sodium)® ophthalmic solution. Other adverse reactions reported with the use of Flurbiren (Flurbiprofen Sodium)® ophthalmic solution include: fibrosis, hyphema, miosis, mydriasis, and ocular hyperemia.
Increased bleeding tendency of ocular tissues in conjunction with ocular surgery has also been reported.
Overdosage will not ordinarily cause acute problems. If accidentally ingested, drink fluids to dilute.
A total of four (4) drops of Flurbiren (Flurbiprofen Sodium)® ophthalmic solution should be administered by instilling one (1) drop approximately every 1/2 hour beginning 2 hours before surgery.
Flurbiren (Flurbiprofen Sodium)® (flurbiprofen sodium ophthalmic solution, USP) is available for topical ophthalmic administration as a 0.03% sterile solution, and is supplied in a white opaque low density polyethylene bottle with a controlled dropper tip and a gray high impact polystyrene cap in the following size:
Storage: Store at 15°-25°C (59°-77°F).
© 2012 Allergan, Inc.
Irvine, CA 92612, U.S.A.
® marks owned by Allergan, Inc.
NDC 11980-801-03 Rx Only
ophthalmic solution, USP) 0.03%
2.5 mL sterile
Depending on the reaction of the Flurbiren after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Flurbiren not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.Is Flurbiren addictive or habit forming?
Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
There are no reviews yet. Be the first to write one!
The information was verified by Dr. Rachana Salvi, MD Pharmacology